Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma to Present at Jefferies Virtual Healthcare Conference
TEL-AVIV, Israel and RALEIGH, N.C. , May 28, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Dror Ben-Asher , RedHill’s Chief Executive Officer, will present a corporate overview at the ...
View HTML
Toggle Summary RedHill Biopharma Provides Q1/2020 Financial Results and Recent Highlights Including Initial Movantik® Revenues
Completed acquisition of Movantik ® from AstraZeneca on April 1, 2020 , and initiated U.S. promotion with net revenues of $7.3 million in April -- Launched commercial sales of Talicia ® in the U.S. in March 2020 ; Talicia ® added to Express Scripts and Prime Therapeutics formularies as an ...
View HTML
Toggle Summary RedHill Biopharma to Host First Quarter Financial Results Conference Call on May 27, 2020
TEL-AVIV, Israel and RALEIGH, N.C. , May 20, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will report its first quarter 2020 financial results on Wednesday, May 27, 2020 . ...
View HTML
Toggle Summary RedHill Biopharma to Present at the UBS Virtual Global Healthcare Conference
TEL-AVIV, Israel and RALEIGH, N.C. , May 11, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Dror Ben-Asher , RedHill’s Chief Executive Officer, will present a corporate overview at the UBS ...
View HTML
Toggle Summary RedHill Biopharma Receives FDA Approval for COVID-19 Clinical Study with Opaganib in the U.S.
The randomized, double-blind, placebo-controlled study aims to enroll up to 40 patients with moderate-to-severe COVID-19 pneumonia in the U.S.  -- All six analyzed moderate-to-severe COVID-19 patients treated with opaganib under compassionate use in Israel were weaned from oxygen and discharged ...
View HTML
Toggle Summary RedHill Biopharma Announces Publication of Talicia® Pivotal Phase 3 Study Results in Annals of Internal Medicine
Talicia ® is approved by the U.S. FDA and promoted by RedHill’s U.S. sales force -- Abstract discussing Talicia pharmacokinetics and exposure-response presented as ePoster at Digestive Disease Week ® (DDW) 2020 TEL-AVIV, Israel and RALEIGH, N.C. , May 05, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma ...
View HTML
Toggle Summary RedHill Biopharma Strengthens Coverage for Talicia® with Preferred Brand Position on Prime Therapeutics NetResults™ National Formulary
Talicia ® is the first and only FDA-approved rifabutin-based therapy for H. pylori infection, designed as a first-line option to address the high resistance of H. pylori bacteria to standard-of-care therapies --- H. pylori bacterial infection is a Group 1 carcinogen and the strongest risk factor ...
View HTML
Toggle Summary Six COVID-19 Patients Treated with RedHill’s Opaganib Under Compassionate Use Show Objective Clinical Improvement
Preliminary data in moderate-to-severe COVID-19 patients treated with opaganib show measurable clinical improvement in all six patients analyzed, including decreased requirement for supplemental oxygenation, higher lymphocyte counts and decreased CRP  -- Five of the six patients have been weaned ...
View HTML
Toggle Summary RedHill Biopharma Announces Agreement with NIAID to Evaluate RHB-107 Against COVID-19
RedHill is pursuing both RHB-107 and opaganib as potential treatments for COVID-19 TEL-AVIV, Israel and RALEIGH, N.C. , April 20, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it has entered ...
View HTML
Toggle Summary IND for COVID-19 with Opaganib Submitted to the FDA by RedHill Biopharma
Proposed study intended to evaluate the safety and efficacy of opaganib in up to 60 patients hospitalized with positive SARS-CoV-2 infection and pneumonia in the U.S. -- Opaganib’s unique mechanism of action has both anti-viral and anti-inflammatory activities, targeting a critical host factor, ...
View HTML